SBP’s newly recruited vice president of Discovery Medicine, Muhammad Al-Hajj, PhD, is leading the charge across a bridge connecting our research discoveries with resources to develop new therapies for cancer patients. His job requires him to have one foot in the research labs and one foot out dancing with commercial pharma, biotech, and venture capital companies willing to fund the development of new cancer drugs.
Tag: GlaxoSmithKline
Sanford-Burnham wins GlaxoSmithKline drug discovery challenge
We’re excited to announce that a joint team of scientists from Sanford-Burnham at Lake Nona and Mayo Clinic has been selected as a winner of GlaxoSmithKline (GSK)’s 2014 Discovery Fast Track Challenge. The Challenge is designed to accelerate the translation of academic research into novel therapies. Researchers from the two organizations will work with partners at GSK to screen the pharmaceutical company’s library of compounds for potential new drugs to treat resistant hypertension, blood pressure that remains high despite treatment with current medications. The Challenge provides resources for small-molecule discovery and offers the opportunity for long-term collaboration. Continue reading “Sanford-Burnham wins GlaxoSmithKline drug discovery challenge”
Sanford-Burnham announces next CEO
We are thrilled to announce that Sanford-Burnham’s Board of Trustees has appointed Perry Nisen, MD, PhD, as the Institute’s chief executive officer and holder of the Donald Bren Chief Executive Chair. In this role, he will lead the Institute and oversee the execution of our new 10-year strategic vision to more quickly translate basic research discoveries into novel treatments that improve human health. Dr. Nisen joins us from GlaxoSmithKline (GSK) – a British multinational pharmaceutical company – where he was senior vice president of Science and Innovation. Continue reading “Sanford-Burnham announces next CEO”